Company intelligence / Profile preview

Rebion

Ownership: Private
Development stage: Commercial

Overview

Rebion has commercialized the blinq.® vision scanner, an FDA-cleared device that rapidly detects amblyopia and strabismus by measuring eye fixation in children and adults. The company’s proprietary Neural Performance Scanning platform uses retinal scanning to quantify neurophysiological function along the optic nerve-brain axis. Their next product, Traq.™, aims to objectively assess visual tracking impairments tied to neurological disorders and is currently in pivotal clinical trials[1].

Therapeutic areas: OphthalmologyNeurology
Modalities: Device
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Rebion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rebion.

Explore the full profile